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Abstract: Fatigue and muscle wasting are common symptoms experienced
by cancer patients. Data from animal models demonstrate that angiotensin is
involved in tumor-induced muscle wasting, and that tumor growth can
independently affect myocardial function, which could contribute to fatigue in
cancer patients. In clinical studies, inhibitors of angiotensin converting
enzyme (ACE) can prevent the development of chemotherapy-induced
cardiovascular dysfunction, suggesting a mechanistic role for the reninangiotensin-aldosterone system (RAAS). In the present study, we
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investigated whether an angiotensin (AT)1-receptor antagonist could prevent
the development of tumor-associated myocardial dysfunction. Methods and
Results: Colon26 adenocarcinoma (c26) cells were implanted into female
CD2F1 mice at 8 weeks of age. Simultaneously, mice were administered
Losartan (10 mg/kg) daily via their drinking water. In vivo echocardiography,
blood pressure, in vitro cardiomyocyte function, cell proliferation assays, and
measures of systemic inflammation and myocardial protein degradation were
performed 19 days following tumor cell injection. Losartan treatment
prevented tumor-induced loss of muscle mass and in vitro c26 cell
proliferation, decreased tumor weight, and attenuated myocardial expression
of interleukin-6. Furthermore, Losartan treatment mitigated tumor-associated
alterations in calcium signaling in cardiomyocytes, which was associated with
improved myocyte contraction velocity, systolic function, and blood pressures
in the hearts of tumor-bearing mice. Conclusions: These data suggest that
Losartan may mitigate tumor-induced myocardial dysfunction and
inflammation.
Keywords: cancer cachexia, cardiovascular function, calcium signaling,
Losartan, cardiomyocyte

Introduction
Cancer cachexia, a syndrome consisting of fatigue, muscle
wasting, and weight loss with or without anorexia, is observed in a
large percentage of cancer patients with incurable disease1 and
contributes to 22 percent of cancer deaths.1,2 New research by our lab
and others has shown that cancer cachexia involves not only the loss
of skeletal muscle, but can also cause pathologic alterations within the
heart.2,3 The resultant effects on myocardial function likely contribute
to fatigue and decreased quality of life in these patients.
We and others have demonstrated tumor-induced cardiac
remodeling and myocardial dysfunction.2–4 Tumor-induced cardiac
remodeling involves increased expression of pro-inflammatory
cytokines, such as interleukin-6 (IL-6).5 as well as ventricular wall
thinning and decreased troponin I levels (a protein involved in cardiac
contraction).2 Previous work from our lab has also shown increased
expression of MAFbx mRNA, a muscle-specific ubiquitin ligase involved
in the ubiquitin proteasome pathway (UPP) of protein degradation, and
Bnip3, a protein involved in the formation of autophagic vesicles, in
mouse hearts inoculated with the colon26 (c26) adenocarcinoma cell
line [3]. We also recently showed that IL-6 levels are elevated in both
the serum and heart muscle in this model.3 Together, these results
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indicate an increase in muscle protein degradation and inflammation in
the heart, and myocardial dysfunction due to growth of the c26
adenocarcinoma.
Current data regarding the impact of the renin-angiotensinaldosterone system (RAAS) on the development of cancer-induced
myocardial dysfunction and its potential therapeutic properties are
inconclusive. Angiotensin II receptor subtypes 1 and 2 (AT1 and 2)
have direct effects on tumor development through the induction of cell
proliferation and vascular endothelial growth factor (VEGF)-induced
angiogenesis.6 Furthermore, the AT2 receptor antagonist Losartan has
been shown to limit tumor-associated angiogenesis, inhibit collagen
synthesis, and attenuate tumor progression. Additionally, Losartan
improves the distribution and efficacy of nanotherapeutics in tumor
therapy.7 Recently, a clinical trial revealed that treatment with a high
dose of the ACE inhibitor Enalapril and also beta-receptor blocker
treatment with Carvedilol prevented the development of
chemotherapeutic-induced myocardial dysfunction.8 These studies
suggest a mechanistic role for the RAAS in cancer treatment-induced
myocardial dysfunction.9 Experimental studies reported preventative
effects of beta-blockers and aldosterone antagonists but not
angiotensin-converting-enzyme (ACE) inhibitors on loss of body weight
and skeletal muscle mass, as well as tumor-induced alterations in
cardiac dimensions in a mouse model of liver cancer-induced cardiac
cachexia and muscle wasting.10 More recent studies indicated that
combined treatments of chemotherapeutics with AT1 receptor
antagonists improved survival.11 However, few studies have
investigated the role of the RAAS in the direct effects of tumor
progression and subsequent myocardial dysfunction and potential
therapeutic prospects.
The RAAS is known to play a major role in myocardial
remodeling and dysfunction. Recently, Angiotensin II (AngII) has been
implicated in skeletal muscle catabolism in tumor-bearing animals via
activation of the UPP of myosin protein degradation. These data
suggest that the RAAS could play a role in tumor-induced myocardial
dysfunction.12–17 In order to examine the impact of the RAAS in tumorinduced myocardial dysfunction and potential therapeutic feasibility,
we treated c26 tumor-bearing mice with Losartan (LOS), an AT1
antagonist, and examined in vivo and in vitro myocardial function,
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blood pressures, and AngII serum concentration following cancer
cachexia development.

Materials and Methods
Animal Model
Animal protocols were approved by the Institutional Care and
Use Committee (IACUC) at the Research Institute at Nationwide
Children’s Hospital and The Ohio State University. One hundred adult
(8 week old) female CD2F1 mice (Harlan) were handled in accordance
with NIH guidelines and housed in a specific pathogen free facility, five
per cage on a 12 hour light/dark cycle. Half of the mice were
inoculated with c26 tumor cells (tumor) and half injected with a similar
saline volume served as healthy controls (control). The c26 cells were
cultured and injected subcutaneously above the scapula, as previously
described.3 Half of the tumor (tumor/LOS) and half of the control
(control/LOS) mice were administered 10 mg/kg of Losartan (LOS)
daily via their drinking water, beginning on the day of tumor cell
injection.
Animals were euthanized on day 19 after tumor cell injection via
pentobarbital injection (20mg/kg for myocyte isolation) or carbon
dioxide inhalation followed by cervical dislocation for tissue collection
as approved by the American Veterinary Medicine Association Panel on
Euthanasia. Hearts were removed, weighed and then used for primary
cardiomyocyte isolation or snap-frozen in liquid nitrogen for molecular
analyses. Gastrocnemius muscles and tumors were removed, weighed,
and snap-frozen in liquid nitrogen.

Real-time Polymerase Chain Reaction
Total RNA was extracted from 100 mg cardiac tissue as
previously described.3 Real time PCR (RT-PCR) for MAFbx (Forward 5′GTGCTTACAACTGAACATATGCA-3′; Reverse 5′-TGGCCCAGGCTGACCA3′), GAPDH (Forward 5′-ATGGTCAAGGTCGGTGTGAACGG-3′; Reverse
5′-AGGGGTGGTTGATGGCAACAATCT-3′) and IL-6 (Forward 5′GCCAGAGTCCTTCAGAGAGATACAGAAACTC-3′; Reverse 5′AGCCACTCCTTCTGTGACTCCAGCTTA-3′) was performed using primer
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pairs and SYBR super mix (BioRad). The TaqMan Gene Expression
Assay was used to detect gene expression of Bnip3 according to the
manufacturer’s instructions. Briefly, 25 μl samples were run in
duplicate in an iCycler iQ5 (BioRad) for 40 cycles at 95°C for 15
seconds and 60°C for 1 minute after the initial 10 minute 95°C
denaturation period. MAFbx, Bnip3, and IL-6 levels were all normalized
to GAPDH expression.3

Plasma Cytokines
Plasma was obtained from mice using an abdominal aortic stick
immediately following euthanasia. Blood was collected in EDTA tubes
and centrifuged at 1500 x g, 10 min, 4°C to separate the plasma.
Plasma levels of interleukin (IL)-1, IL-6, IL-10, IL-12, interferongamma (IFN-γ), tumor necrosis factor-α (TNF-α), and chemokine (CX-C motif) ligand 1 (CXCL1) were measured using the MSD Mouse Proinflammatory 7-Plex Ultra-Sensitive Kit (Meso Scale Discovery
K15012C) according to the manufacturer’s instructions.

Echocardiography
On day 19 post-injection, in vivo cardiac function was assessed
in 56 mice (15 control, 14 control/LOS, 17 tumor, and 10 tumor/LOS)
via echocardiography using a VisualSonics Vevo 2100 Ultra High
Resolution In Vivo Imaging System (VisualSonics, Toronto, ON,
Canada) as previously described.3,18 Briefly, mice were anesthetized
with 1.5% isofluorane in an anesthesia induction chamber. Following
the induction of anesthesia, mice were placed on a warming pad, and
connected to a three lead electrocardiogram monitor. During
echocardiographic analyses, mice were continuously sedated with
1.0% isoflurane (in 100% O2) to receive identical anesthetic conditions
for all groups. Left ventricular systolic diameter (LVESd), left
ventricular diastolic diameter (LVEDd) and left ventricular posterior wall
thickness at systole (PWTs) and diastole (PWTd) were measured using
the M-mode echocardiogram. Fractional shortening (FS) was calculated
using FS=(LVEDd-LVESd)/LVEDd*100. Ejection fraction (EF) was
calculated using the following equation: EF=(LVEDdLVESd/LVEDd)*100. Stroke volume (SV) was calculated using the
Doppler flow Velocity-Time Integral (VTI) at the LV outflow tract
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(LVOT) and the aortic diameter (Ao), (LVOT2 * 0.785 * Ao VTI). LV
mass was calculated using the equation (left ventricular anterior wall
(LVAW)+LVEDd+ PWTd)3-(LVEDd)3.19

Ventricular Myocyte Isolation and Functional
Assessment
Following echocardiography, cardiomyocytes were isolated as
previously described3,18,20–23 Briefly, the hearts were removed and
retrograde perfusion was performed with buffer, followed by 0.25
mg/ml Liberase DH (Roche), 0.14 mg/ml 2.5% Trypsin (Gibco) and
12.5 μM CaCl2 for 5–7 minutes. Cells were dissociated by repeated
pipetting and then filtered to remove cellular debris. Cardiomyocytes
were exposed to increasing concentrations of CaCl2 (to minimize the
calcium paradox) and then plated on laminin-coated glass chambers.
Cardiomyocyte sarcomere function was examined using the Soft
Edge MyoCam system (IonOptix Corporation), as previously
described.3,18,20–23 Only myocytes with normal sarcomeric appearance
(absence of sarcomeric blebs) were used in these experiments. Peak
shortening (sarcomere BL% peak height; cellular equivalent of %FS),
time to 90 percent of peak shortening (TPS90), time to 90 percent
relengthening (TR 90), and velocities of shortening (-dL/dt) and
relengthening (+dL/dt) were measured following stimulation at 1 Hz.

Assessment of Cardiomyocyte Calcium Signaling
Ca2+ transients and caffeine-induced Ca2+ release were
measured in isolated myocytes loaded with fura-2 AM, as previously
described.3,18,20–23 Briefly, myocytes were incubated with 0.5 μM fura-2
AM for 10 minutes and fluorescence was recorded using the Ionoptix
dual-excitation fluorescence photomultiplier system through a 40x oil
immersion objective. Fluorescence was achieved by excitation at 360
nm, followed by 380 nm, and emission was detected between 480–520
nm. For Ca2+ transient measurements, cells were stimulated at 0.5 Hz
and changes in cytosolic Ca2+ levels were inferred from the ratio of
fluorescence intensity at the two wavelengths. Caffeine-induced Ca2+
release from the SR was assessed in fura-2AM loaded cells by rapidly
applying 20 mM caffeine and recording the resulting transient.
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Integration under the resulting caffeine-induced Ca2+ release curve
was calculated as an index of SR Ca2+ concentration.
Calcium sparks were measured by loading isolated
cardiomyocytes with 20 μM Fluo-3 AM and 5% pluronic acid in
Tyrode’s Solution, which contained, in mM: 140 NaCl, 4 KCl,, 2 CaCl2,
1 MgCl2, 10 glucose, and 10 HEPES; pH 7.4 with NaOH. Cells were
imaged using an inverted Zeiss 710 confocal microscope.24

GSSG/GSH Assay
The ratio of oxidized-to-reduced glutathione (GSSG/GSH) in left
ventricular homogenates in all groups was measured as previously
described,25 as a global measure of antioxidant status in the heart.

Blood Pressure Measurements
Blood pressures were measured at baseline (prior to
tumor/control injection), 12, and 18 days post injection using a
computerized tail cuff system (BP-2000 Series II Visitech System Inc.,
Apex, North Carolina) as described previously.18 Mice were trained
before the procedure for 5 consecutive days to avoid anxiety during
the procedure. In order to minimize procedure-induced effects,
measurements were separated by 20 seconds to restore blood flow
through the tail and preliminary assessments were not used for
analyses. Ten values were recorded and averaged for analyses of the
data from each mouse.

Angiotensin II Immunoassay
Blood was collected 18 days following tumor cell or sham
injection and the serum was separated using Microtainer Serum
Separator Tubes (BD, Franklin Lakes, NJ). Angiotensin II
concentrations were assessed using a Fluorescent Immunoassay
(Phoenix Pharmaceuticals, Inc. Burlingame, CA). According to the
manufacturer’s instructions, serum and primary antibody were
incubated on a pre-coated fluorescent plate at 4°C overnight.
Subsequently, a biotinylated Angiotensin-II peptide was added and
allowed to incubate for 1.5 hours at room temperature. After washing,
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samples were incubated with a Streptavidin-horseradish peroxidase
conjugate (SA-HRP) for 1 hour at room temperature before the
substrate was added and the reaction proceeded for 20 minutes before
the relative fluorescence was determined using a fluorescent plate
reader at an excitation and emission maxima of 325 and 420 nm
respectively. Results were obtained by comparing the optical density
to a standard series using 4-parameter logistic curve fitting software.

Colon26 (c26) Adenocarcinoma Cell Proliferation Assay
The effects of Losartan on c26 Adenocarcinoma cell proliferation
were determined using a Tryptan blue assay. Cells were seeded at the
same density onto separate plates and allowed to adhere overnight.
The following day, either 1 mM or 10 mM of Losartan was added to the
cells as previously described.26 Once the control cells reached
confluence, the media was removed and the cells were trypsinized,
centrifuged and re-suspended in DPBS. Cells were mixed together with
Trypan blue and viable cells were counted on an Improved Neubauer
Hemocytometer and expressed as cells/mL.

Statistical Analyses
Data were analyzed using a two-way ANOVA to uncover main
effects of tumor and drug treatment and interaction effect of tumor
and drug treatment on outcome measures, followed by Bonferroni
post-hoc testing to uncover specific group differences. For blood
pressure measurements, the mean of five measures was used for
statistical analyses. Statistical significance was set at p<0.05. Data are
reported as mean ± standard error of the mean (SEM).

Results
Losartan treatment prevented tumor-related muscle
wasting and reduced tumor progression
Body weights, excluding tumor weights, were assessed on day
19 and not different between tumor/sham and control/sham or
tumor/LOS and control/LOS treated mice. However, tumor/LOS
treated mice had lower body weights compared to control/sham
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treated mice and statistical analyses indicated that Losartan treatment
had a significant effect (p<0.05) on body weight (Table 1). Relative
gastrocnemius weights were significantly lower in tumor/sham mice
compared to control/sham mice. However, gastrocnemius weights
were not different between tumor/LOS and control/LOS treated mice.
Statistical analyses indicated that tumor cell injection significantly
reduced gastrocnemius muscle weight relative to body weight
(p<0.05), with no effect of Losartan treatment (p=.06) on relative
gastrocnemius weights (Table 1). These data suggest that Losartan
mitigated muscle wasting in the tumor-bearing mice. Heart weights
were not different between groups and neither tumor growth nor
Losartan treatment had an effect on relative heart weight (Table 1).
Tumor weights were significantly lower in tumor/LOS mice compared
to tumor mice (p=.01), suggesting that Losartan treatment
significantly reduced tumor growth.
Table 1. Normalized body weight (exclusive of tumor weight), heart weight,
gastrocnemius weight and tumor weight in mice. Normalized gastrocnemius
and heart weight was calculated by dividing the measured tissue weight by
the body weight. Data were analyzed using two-way ANOVA (tumor growth,
Losartan treatment) and Bonferroni post hoc tests. Tumor weights were
analyzed using student’s t test.
Body
weight
(excl.
tumor
weight)
(g)

Gastrocnemius
weight (rel.)
(mg/g)

Gastrocnemius
weight (abs.) (g)

Heart
weight
(rel.)
(mg/g)

Heart
weight
(abs.)
(mg)

Tumor
weight (g)

control/sham
(n=25)

21.4±0.4

4.76±0.2

9.88±0.24

6.27±0.27

133±2

N/A

tumor/sham
(n=26)

19.6±0.4

4.22±0.2*

7.85±0.34*

6.87±0.37

132±2

1.26±0.1

control/LOS
(n=20)

20.7±0.4

4.89±0.6

9.69±0.37

6.22±0.3

128±2

N/A

tumor/LOS
(n=17)

18.4±0.6*

4.91±0.2

8,36±0.27*

6.63±0.5

118±2

0.88±0.1*

*p<0.05

compared to respective control.

Tumor-related cardiac degradation and inflammation is
attenuated by Losartan treatment
Cardiac MAFbx, Bnip3, and IL-6 mRNA expression were
significantly increased in tumor/sham compared to control/sham mice.
However, cardiac MAFbx and Bnip3 mRNA expressions were not
increased in tumor/LOS treated mice compared to control/LOS and
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control/sham treated mice. IL-6 expression was not significantly
different in tumor/LOS compared to control/LOS mice, but it was
significantly lower than in tumor/control mice. Statistical analyses
indicated effects of tumor cell injection on cardiac MAFbx (p<.001),
Bnip3 (p=.01), and IL-6 (p<.001) mRNA expression. Losartan
treatment had a significant effect on IL-6 mRNA expression (p<.05)
alone, indicating that Losartan reduced expression of IL-6 mRNA in the
hearts of both tumor-bearing and control mice (Figures 1A–C).

Figure 1. Gene expression of MAFbx (A), Bnip3 (B) and IL-6 (C) in cardiac tissue of
tumor-bearing and Losartan-treated mice. Gene expression levels were determined
using RT-PCR and are normalized to GAPDH expression. A, MAFbx, an indicator of
ubiquitin proteasome function; B, Bnip3, an indicator of cellular autophagy; C, IL-6, an
inflammatory cytokine. Data were analyzed using two-way ANOVA and Bonferroni post
hoc pairwise comparisons. * p<0.05 compared to respective control. n=6
control/sham, n=5 tumor/sham, n=6 control/LOS, n=7 tumor/LOS.
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Losartan treatment attenuated tumor-associated
increases in plasma cytokine levels
IL-6 and CXCL1 protein concentrations were significantly
increased in tumor/sham and tumor/LOS compared to respective
controls (Figures 2A&B). IL-10 protein concentrations were increased
in tumor/sham compared to control/sham but not in tumor/LOS
compared to control/LOS treated mice (Figure 2C). Statistical analyses
revealed an effect of tumor cell injection on plasma levels of IL-6
(p<.0001), CXCL1 (0.0001), IL-10 (p<0.01), and IL1-β (p<0.05)
(Figures 2A–D) and an effect of Losartan treatment on plasma TNF-α
levels (p<0.05) (Figure 2E). Neither tumor cell injection nor Losartan
treatment affected plasma levels of IFN-γ (Figure 2F).

Figure 2. Plasma pro-inflammatory cytokine levels in tumor-bearing and Losartantreated mice. Cytokine levels were determined using the Pro-inflammatory 7-Plex
Ultra-Sensitive Kit. Data were analyzed using two-way ANOVA (tumor growth and
Losartan treatment) and Bonferroni post hoc pairwise comparisons. * p<0.05
compared to respective control, n=10.
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Losartan treatment prevented tumor-associated
changes in LV dimensions and preserved myocardial
function
Tumor cell injection reduced fractional shortening (FS), ejection
fraction (EF), stroke volume (SV), posterior wall thickness in diastole
(PWTd), and systole (PWTs) and increased systolic left ventricular
dimension (LVEDs) in tumor/sham mice compared to control/sham
mice. Losartan treatment prevented tumor-associated alterations in
left ventricular dimensions and function. EF, EF, SV, PWTd, PWTs, were
significantly greater and LVEDd, and LVEDs significantly lower in
tumor/LOS treated mice compared to tumor/sham mice. There were
no differences between control/LOS and tumor/LOS treated mice.
Heart rates were not different between groups. Statistical analyses
indicated effects of tumor cell injection, Losartan treatment, and an
interaction effect on LVEDs (p<0.001), PWTs (p<0.05), SV (p<0.01),
EF (p<0.0001), and FS(p<0.0001) (Table 2). These results indicate
that tumor cell injection reduced cardiac wall diameter and myocardial
contractility, with Losartan treatment mitigating the effects of tumor
cell injection on cardiac diameter and myocardial function.
Table 2. In vivo echocardiographic parameters in tumor-bearing and
Losartan-treated mice. Fractional shortening (FS), ejection fraction (EF), left
ventricular end diastolic diameter (LVEDd), left ventricular end systolic
diameter (LVESd), posterior wall thickness during diastole (PWTd), posterior
wall thickness during systole (PWTs) and stroke volume (SV) in tumor-bearing
and LOS-treated animals. Values were calculated from m-mode
electrocardiograms as shown in Figure 3. Data were analyzed using two-way
ANOVA (tumor growth and Losartan treatment) and Bonferroni post hoc tests.
control/sham (n=15) tumor/sham (n=17) control/LOS (n=14) tumor/LOS (n=10)
FS (%)

37.6±1.1

23.0±0.85*
*

38.5±0.9#

35.9±0.5#

#

66.0±0.8#

EF

68.2±1.4

46.4±1.4

LVEDd (mm)

3.87±0.1

4.18±0.1

3.96±1.9

3.98±0.1

LVEDs (mm)

2.45±0.1

3.21±0.1*

2.47±0.1#

2.55±0.1#

PWTd (mm)

0.77±0.3

0.63±0.01*

0.74±0.03#

0.71±0.03

PWTs (mm)

1.10±0.04

0.88±0.02*

1.14±0.03#

1.06±0.03#

*

68.8±1.1

38.9±1.5#

SV (μl)

35.0±1.9

24.4±0.8

HR (BPM)

455±11

460±12

449±8

442±9

83.80±2.94

104.08±7.91

93.10±5.67

LV mass (mg) 93.25±5.48

36.0±1.7

#

*p<0.05

compared to respective control,
#p<0.05 compared to tumor/sham.
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Furthermore, there was an effect of tumor cell injection
(p<.001) and an interaction effect (p<0.05) of tumor cell injection and
Losartan treatment on PWTd.; post hoc analyses revealed no
significant differences between tumor/LOS and either group of control
mice, suggesting that Losartan mitigated the effects of tumor cell
injection. However, neither tumor cell injection nor Losartan treatment
affected LVEDd (Figure 3, Table 2).

Figure 3. Representative M-mode in vivo echocardiographic images obtained at the
mid-papillary muscle level of tumor-bearing and Losartan-treated mice. Images
include electrocardiogram and respiratory traces at the bottom.

Tumor-induced cardiomyocyte dysfunction is improved
with Losartan treatment
Percent sarcomeric peak shortening (%PS, the cellular
equivalent of in vivo fractional shortening) (Figure 4A) was not
affected by either tumor cell injection or Losartan treatment. However,
time-to-90% peak shortening (TPS90) and time-to-90 percent
relengthening (TR90) were significantly increased in tumor/sham
compared to control/sham treated mice and further increased in
tumor/LOS compared to tumor/sham treated mice. Statistical analyses
indicated effects of tumor cell injection on TPS90 (p<.0001) and TR90
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(p<0.05), and effects of Losartan treatment on TPS90 (p<.001) and
TR90 (p<0.05). These data suggest that the effects of Losartan
treatment on peak shortening and relengthening were independent of
the tumor condition and could be related to the tendency of Losartan
to cause hypertrophy.27,28

Figure 4. In vivo myocyte function in tumor-bearing and Losartan-treated mice. A,
percent peak sarcomere shortening (Sarcomere BL). B, time to 90 percent of peak
shortening (TPS90). C, time to 90 percent relengthening (TR90). D, velocity of
myocyte shortening. E, velocity of myocyte relengthening. Data were analyzed using
two-way ANOVA (tumor growth and Losartan treatment) and Bonferroni post hoc
pairwise comparisons. * p<0.05 compared to respective control. Myocyte cell
numbers: n=70 cells/12 mice control/sham, n=97 cells/17 mice tumor/sham, n=45
cells/4 mice control/LOS, n=61 cells/8 mice tumor/LOS.

In contrast, depolarization velocity (-dL/dt) was increased in
tumor/sham compared to control/sham and tumor/LOS treated mice.
Statistical analyses indicated an effect of Losartan treatment
(p<0.001) and an interaction between tumor cell injection and
Losartan treatment (p<0.005) on -dL/dt. The velocity of relengthening
(+dL/dt) was significantly increased in tumor/sham compared to
tumor/LOS mice. Statistical analyses indicated an interaction of tumor
cell injection and Losartan treatment on +dL/dt (p<0.01) (Figures 4D
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& E). These findings suggest an effect of Losartan on the mechanics of
sarcomeric function that requires further mechanistic investigation.

Losartan treatment attenuated tumor-induced changes
in calcium signaling
Calcium transient amplitude and calcium reuptake velocity were
increased in tumor/sham compared to control/sham and tumor/LOS
mice. Furthermore, calcium transient amplitude was increased in
tumor/LOS but maximum velocity of calcium transients was not
different compared to control/LOS treated mice. Statistical analyses
revealed effects of tumor cell injection and Losartan treatment on
calcium transient amplitude (p<.001), and an additional interaction
effect of tumor cell injection and Losartan treatment on calcium
reuptake velocity (p<.001) (Figure 5A–B). These effects on calcium
transients and reuptake suggest that Losartan treatment normalized
calcium currents in the myocytes of tumor-bearing mice.

Figure 5. Cardiomyocyte calcium signaling in tumor-bearing and Losartan-treated mice. A, amplitude of
stimulated Ca2+ transients. B, amplitude of calcium sparks. C, amplitude of caffeine induced Ca 2+ release. D,
Integration under the caffeine-induced Ca2+ release curve as an index of SR Ca2+ concentration. Data
analyzed using two-way ANOVA (tumor growth, Losartan treatment), followed by Bonferroni post hoc
pairwise comparisons. * p<0.05 compared to respective control. Myocyte cell numbers for calcium analysis:
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n=27 cells/11 mice control/sham, n=40 cells/14 mice tumor/sham, n=29 cells/4 mice control/LOS, n=52
cells/8 mice tumor/LOS.

Spark amplitude was lower in control/LOS compared to
control/sham treated mice. Statistical analyses indicated an effect of
Losartan on spark amplitude (p<0.01) (Figure 5C). Caffeine-induced
calcium release was increased in tumor/LOS compared to control/LOS
and tumor/sham treated mice. Statistical analyses indicated an effect
of tumor cell injection on caffeine induced calcium release (p<0.005)
(Figure 5D).

GSH/GSSG levels are increased in hearts of tumorbearing mice
Left ventricular GSH/GSSG levels were not different between
groups; however, statistical analysis indicated an effect of tumor cell
injection (p<0.05) on the GSH/GSSG ratio (Figure 6).

Figure 6. Oxidative stress in ventricular tissue of tumor-bearing and Losartan-treated
mice. The ratio of GSH/GSSG was used to approximate oxidative stress in left
ventricular tissue. Data analyzed using two-way ANOVA (tumor growth, Losartan
treatment), followed by Bonferroni post hoc pairwise comparisons. No significance was
observed with Losartan treatment. n=5.
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Tumor growth and Losartan treatment affected blood
pressure
Systolic blood pressure was lower in control/LOS compared to
control/sham treated mice 12 days after tumor cell injection (data not
shown). Statistical analyses indicated effects of Losartan treatment
(p<0.05) and an interaction between Losartan treatment and tumor
cell injection (p<0.05) on systolic blood pressure. Diastolic blood
pressures and developed pressures were not different between groups
12 days after tumor cell injection and/or Losartan treatment. However,
18 days post tumor cell injection systolic and developed pressures
were significantly lower in tumor/sham compared to control/sham
mice. However, there was no difference in tumor/LOS treated mice
compared to control/sham or control/LOS treated mice. Statistical
analyses indicated interaction effects of tumor cell injection and
Losartan treatment on systolic (p<0.05) and developed (p<0.001)
blood pressures. Furthermore, diastolic blood pressures were lower in
control/LOS and tumor/LOS treated mice compared to respective
control/sham and tumor/LOS treated mice. Statistical analyses
indicated an effect of Losartan treatment on diastolic blood pressure
(P<0.05) (Table 3).
Table 3. Blood pressure in tumor-bearing and Losartan-treated mice. Systolic
blood pressure, diastolic blood pressure and developed pressure on days 12
and 18. days after tumor cell injection. Data were analyzed using two-way
ANOVA (tumor growth and Losartan treatment) and Bonferroni post hoc tests.
control/sham
(n=4)

tumor/sham
(n=4)

control/LOS
(n=5)

tumor/LOS
(n=5)

D12 Systolic blood
pressure (mmHg)

120±1

106±2

103±4

107±4

D12 Diastolic blood
pressure (mmHg)

46±4

53±5

46±4

53±10

D12 developed pressure
(mmHg)

74±3

54±6

58±6

55±10

D18 Systolic blood
pressure (mmHg)

125±4

99±3*

103±3

109±9

D18 Diastolic blood
pressure (mmHg)

58±4

59±7

41±3

41±2

D18 developed pressure
(mmHg)

68±7

40±6*

61±2

68±7

*p<0.05

compared to respective control.
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Tumor cell injection increased Angiotensin II serum levels
Angiotensin II serum levels from tumor/control and tumor/LOS treated
mice were increased compared to sham/control and sham/LOS treated
mice, respectively. Statistical analyses indicated a significant effect of
tumor cell injection on Angiotensin II serum levels (Figure 7).

Figure 7. Angiotensin II Protein levels in mouse serum of tumor-bearing and Losartan
treated mice 18 days after tumor cell or sham injection. Data were analyzed using
two-way ANOVA (tumor growth, Losartan treatment), followed by Bonferroni post hoc
pairwise comparisons. * p<0.01 compared to control, n=4.

Inhibitory effects of Losartan on c26 Adenocarcinoma
cell proliferation
Losartan treatment significantly inhibited the proliferation of c26
adenocarcinoma cells in vitro compared to non-Losartan treated
control cells (p<0.001) (Figure 8).
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Figure 8. Effects of Losartan on c26 Adenocarcinoma cell proliferation. Cells were
cultured with 1 mM/L, 10 mM/L or without Losartan for 3 days. Data were analyzed
using one-way ANOVA. Losartan significantly inhibited the proliferation of c26
Adenocarcinoma cell at both concentrations. p<0.001, n=6.

Discussion
As shown in Table 1, treatment with Losartan preserved
gastrocnemius muscle mass in c26 tumor-bearing mice, without
improving body weight. The RAAS affects fatty acid and glucose
metabolism and ACE deficiency, resulting in a reduction in body
weight.29 Based on these data, we speculate that the observed
reduction in body weight of tumor-bearing and Losartan treated mice
could be related to Losartan-induced alterations of the RAAS and
subsequent effects on glucose and fatty acid metabolism. Tumor
bearing and Losartan treatment had no significant effects on heart
weight normalized to body weight. Based on the results of others,
however, it is likely that heart mass may have decreased had the
tumor-bearing mice been allowed to develop more severe cachexia
prior to euthanasia and the presented results are not due to cachexia
but tumor presence.5
Echocardiographic studies confirmed our earlier findings of
systolic dysfunction in c26 tumor-bearing mice3 (Table 2). This
dysfunction was attenuated by treatment with Losartan. These data
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are in accordance with others that investigated in liver cancer induced
cardiac failure and reported an attenuation of tumor induced left
ventricular dysfunction in beta blocker and mineralocorticoid receptor
antagonist treated mice.10 Our data suggest that Losartan may be
useful in preserving myocardial function in patients with cancer
associated cardiac dysfunction.
Tumor cell injection prolonged contraction and depolarization
velocities of isolated cardiomyocytes. At the cellular level, tumor
progression prolonged TPS90 and TR90 in isolated cardiomyocytes.
However, Losartan treatment also prolonged TPS90 and TR90 in
myocytes from tumor and control mice, such that there were no longer
any differences between the myocytes of tumor and control mice
(Figures 4B and 4C). These data suggest that other non-myocyte cell
types could play a role in normalization of myocardial function in the
tumor-bearing mice, such as activation of proteins involved in the
production of the extracellular matrix. Other possible explanations for
the improvements in in vivo cardiac function, but not in vitro cellular
parameters, include myocyte apoptosis or a change in intracellular
communication.
We also examined the direct effects of Losartan treatment on
blood pressure. Our results show a reduction of systolic blood pressure
and developed pressure, representing the circulatory consequences
and confirming the reported in vitro and in vivo results indicating
myocardial dysfunction 18 days following tumor cell injection.
Distinctly, Losartan affected blood pressure in the presence as well as
the absence of tumor, suggesting direct effects of Losartan on blood
pressure. The reduction in blood pressure indicates a direct effect of
Losartan on the circulation (Table 3).
It is clear that Losartan improved myocardial function in this
mouse model of cancer cachexia and there are several plausible
mechanisms. Our data indicate that Losartan altered pro-inflammatory
activity as observed by a decrease in IL-6 mRNA expression in the
heart, which is thought to be a key step in activation of the UPP of
myosin degradation.30 Activation of the UPP is a known effect of
AngII16 and pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-α
induced NF-κB activation have been reported to be the mechanisms of
altered striated muscle mass in tumor-bearing cancer models,31 thus it
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is not surprising that Losartan treatment would preserve
gastrocnemius muscle mass in tumor-bearing mice (Table 1).
Losartan treatment affected Ca2+ transient amplitude in
cardiomyocytes from both the control and tumor groups (Figure 5A),
but affected the area under the Ca2+ release curve (Figure 5D), which
is an index of SR Ca2+ levels, in only the tumor-bearing mice. The
change in the caffeine-induced Ca2+ release curve was potentially due
to Losartan increasing the expression of NCX,32 which is the sole
channel responsible for clearing Ca2+ from the cytosol during
treatment with caffeine. It is, however, unlikely that Ca2+ signaling is
the entire mechanism of improvement following Losartan treatment as
tumor-induced changes in the amplitude of the Ca2+ transient are
unaffected by Losartan. However, these data require further
investigation.
The increase in the relative amount of MHC-β is consistent with
an earlier report5 from a study using the same tumor-bearing model.
The increased amount of MHC-β in the tumor-bearing mice likely
contributed to the observed prolonged time to peak shortening in
isolated myocytes. Even small differences in the MHC isoform
composition of isolated cardiomyocytes can affect power output, with
an increase in the amount of MHC-β being associated with reduced
power.33–35 However, an increase in the amount of MHC-β is associated
with increased economy of myocardial contraction,36 potentially
providing a beneficial adaptation in the tumor-bearing mice, which
eventually develop a reduction in cardiac wall thickness.2 The increase
in the amount of MHC-β was also associated with an increase in the
amount of one of the apparent MHC-α fragments (MHC-α′) in tumorbearing, which could also be an adaptation to maintain force
generating ability with increased economy. Interestingly, increased
MHC breakdown has also been reported in skeletal muscle with the
same tumor-bearing mouse model.37
The relative amount of MHC-β was not different between
control/LOS and tumor/LOS mice. This is consistent with Losartan
reversing the increase in the mRNA and protein levels of MHC-β
following induced heart failure in rats.38–40 There was an increase in
the relative amount of apparent MHC-α proteolytic fragments in
Losartan-treated mice. The responsible mechanism is not known, but it
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is possible that there is increased proteolytic activity associated with
changes in MHC expression and replacement in myofibrils during
Losartan treatment.
Ca2+ transient amplitude was altered in tumor/LOS mice (Figure
5A), with no change in cardiomyocyte peak shortening (Figure 4A).
This suggests that there could have been a change in myofilament
Ca2+ sensitivity, which is often observed during ventricular
hypertrophy.41 This would also be a potential explanation for the
decrease in myocardial function in the tumor-bearing mice.
AngII is known to increase ROS production in various
diseases.42–44 AngII causes the formation of reactive oxygen species in
vivo, mediated by AT2 in response to hypertension. Thus, we also
examined the GSH/GSSG ratios as a marker for the presence of
oxidative stress in heart tissue as a potential mechanism of myocardial
dysfunction observed in tumor-bearing mice. While tumor presence did
increase overall GSH/GSSG levels in heart tissue, Losartan treatment
surprisingly had no effect on production of this particular marker of
oxidative stress (Figure 6). AngII receptor blockers have been shown
to reduce the production of ROS in the kidneys in a mouse model of
hypertension-induced cardiomyopathy. Based on these reports, our
data suggest that the observed improvement of cardiac function could
be related to the direct effects of other reactive oxygen species or
hormone related improvement in blood pressure. AngII is not likely to
be involved in the direct cardiac mechanism of action for Losartanmediated improvements in myocardial function in tumor-bearing mice.
Losartan is a selective AT1 receptor antagonist without serious
adverse effects that is commonly used for the treatment of
hypertension. In our model Losartan treatment reduced diastolic blood
pressure in control and tumor mice, but prevented tumor associated
reduction in systolic blood pressure and most importantly developed
pressure.
Accumulating evidence supports the notation that the RAAS
directly impacts tumor progression through tumor cell proliferation and
tumor angiogenesis. Furthermore, Losartan has been shown to
improve the effects of chemotherapeutics, potentially through an
enhancement of drug delivery in breast and pancreatic cancer
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models.45 Therefore, another plausible explanation for the observed
Losartan associated prevention of tumor-associated development of
cardiac dysfunction could be linked to direct effects of Losartan on
tumor cells and the tumor itself. However, the direct impact of
Losartan on adenocarcinoma cell proliferation has not been
investigated. Thus, we examined the effects of Losartan on c26
adenocarcinoma cells proliferation and tumor progression. Our data
indicated that Losartan treatment impaired c26 adenocarcinoma cell
proliferation in vitro and reduced tumor weight in vivo. In summary,
our in vitro data indicate a direct effect of Losartan on tumor cells,
reducing c26 tumor cell proliferation. Antagonizing the AT1 receptor by
Losartan treatment could be a potential mechanism for the herein
reported reduction in tumor progression and subsequent prevention of
tumor associated development of cardiac dysfunction.
Taken together, our data indicate that Losartan treatment
impaired c26 adenocarcinoma cell proliferation in vitro, reduced tumor
weight in vivo, prevented the expression of in cardiac degeneration
and inflammation involved mediators and attenuated the development
of tumor-associated cardiac dysfunction in vivo and in vitro. Losartan
has been shown to reduce VEGF concentrations in various models,
which subsequently impairs vascular formation in neoplastic tissue
affecting tumor presence. In our c26 adenocarcinoma model Losartan
treatment reduced tumor weight and improved tumor induced cardiac
dysfunction and our in vitro data suggest, that the reduction in tumor
weight may be due to Losartan induced reduction in c26
adenocarcinoma cell proliferation. However, one limitation of our study
is that the presented data do not indicate if the beneficial effects of
Losartan on tumor-induced cardiac dysfunction are based on direct
effects of Losartan on tumor cells or the prevention of tumor
progression and secondary to the heart. Hence, we cannot rule out
primary effects of Losartan to the heart that directly prevent the
development of tumor-induced cardiac dysfunction.
Our herein presented results provide promising new insights into
the potential role for Losartan, a widely used AT1 receptor antagonist
that has no serious side effects, for the treatment of tumor-induced
myocardial dysfunction in cancer patients.
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Highlights




Losartan treatment has a beneficial effect on tumor-mediated cardiac
dysfunction.
Reactive oxygen species are a key component of cancer-mediated
cardiac dysfunction.
Treatment with Losartan affects tumor cell growth in vitro.

Supplementary Material
Material and Methods
Assessment of MHC Isoform Composition. Left ventricular
homogenates were prepared from the hearts of control and c26 tumorbearing mice, as in Reiser and Kline [1]. Myosin heavy chain (MHC) isoform
composition of left ventricular homogenates was examined using SDS-PAGE
and scanning densitometry. Gels were also run for mass spectrometry and
immunoblotting. Separating gels consisted of 7% acrylamide, with a 50:1
acrylamide:bis-acrylamide crosslinking ratio, and 5% (v/v) glycerol.
Additional details for the separating and stacking gels were as described in
Reiser and Kline [1]. The gels were run for 21 hours at 8ºC and 230 constant
volts. Silver-staining and scanning of the gels were as described previously
[1, 2], except that the gels were scanned before drying. One gel was stained
with Coomassie Blue and bands were excised and analyzed with liquid
chromatography, coupled to tandem mass spectrometry, in the Campus
Chemical Instrument Center at The Ohio State University [3]. Another gel was
used for immunoblotting that was probed with an MF 20 antibody, which
recognizes all sarcomeric MHC isoforms (supernatant from the Developmental
Studies Hybridoma Bank was diluted to 1:50). Protein bands were detected
with a secondary antibody conjugated with alkaline phosphatase, as
previously described [4].

Results
Changes in MHC Isoforms: The amounts of MHC- and MHC- were
determined by densitometry of silver-stained gels (example shown in panel A
of Figure S1). There was a small, but significantly (P<0.005) greater amount
of MHC-, relative to the total amount of MHC, in the left ventricle of tumorbearing mice, compared to control mice. There was no difference in the
relative amount of MHC- between control/LOS and tumor/LOS mice. Several
protein bands, with electrophoretic mobilities that were greater than that of
MHC isoforms, were observed on the same gel. An immunoblot with an
antibody that recognizes all sarcomeric MHC isoforms (MF 20, supernatant,
diluted 1:50, Developmental studies Hybridoma Bank, University of Iowa,
Iowa City, IA) was run and three prominent bands were detected,
corresponding to MHC-, MHC- and a band with greater mobility (panel C of
Figure S1). The latter band and another band, with even greater mobility and
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which was not suffucently abundant to be detected by the antibody but was
visible on stained gels, were excised from a Coomassie-stained gel. These
bands were submitted for analysis by mass spectrometry in the Ohio State
University Campus Chemical Instrument Center.
The six peptides from the digestion of both excised bands that had the
strongest matches with MHC- were the same for both bands. The MOWSE
scores from mass spectrometry were 8227 and 2975 for MHC-’ and MHC-’’,
respectively. These scores far exceed the score (i.e., 53) that is associated
with a significant probability of correct identification. Given the high MOWSE
scores, we conclude that these bands are likely to be proteolytic fragments of
MHC- and are labeled as MHC-’ and MHC-’’. The relative amounts of MHC’ and MHC-’’ were individually quantitated relative to the total MHC- pool
(i.e., the sum of MHC + MHC-’ + MHC-’’) in each sample. The relative
amount of MHC-’ was significantly greater in tumor-bearing mice, compared
to control mice, both with and without Losartan treatment. Losartan
treatment did not affect the relative amount of MHC-’ in control mice, but
the relative amount of MHC-’ was greater in tumor-bearing mice that were
treated with Losartan, compared to untreated tumor-bearing mice. There was
no difference in the relative amount of MHC-’’ between untreated control and
tumor-bearing groups. Losartan treatment was associated with an increase in
the relative amount of MHC-’’ in control mice, but not in tumor-bearing mice.
Figure

Figure. S1. Cardiac myosin heavy chain (MHC) isoforms and proteolytic fragments in control and
tumor-bearing mice. The MHC region of an SDS gel loaded with left ventricular samples from
control and tumor-bearing mice, with or without Losartan treatments. B, quantitation of the
amount of MHC-, relative to total intact MHC (MHC- + MHC-), from scanning densitometry of
silver-stained gels and quantitation of the amounts of two proteolytic fragments of MHC- (MHCα’ and MHC-α”), relative to the total MHC- pool (MHC- + MHC-’ + MHC-’’), from scanning
densitometry of silver-stained gels. * p<0.05 compared to respective control (n=6).
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